Nascent Pharma Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	1.03	2.16	6.69	4.6	1.71	2.31
Revenue Growth (YoY)	-57.73%	-67.75%	45.22%	169.28%	-25.84%	244.82%
Cost of Revenue	1.38	1.8	4.07	1.61	0.28	0.6
Gross Profit	-0.34	0.36	2.61	2.99	1.43	1.71
Selling, General & Admin	4.03	4.75	12.62	9.64	8.97	6.49
Amortization of Goodwill & Intangibles	-	-	-	-	-	0.14
Other Operating Expenses	3.1	3.1	4.17	3.62	-	0.95
Operating Expenses	7.13	7.85	16.78	13.26	8.97	7.6
Operating Income	-7.47	-7.49	-14.17	-10.27	-7.54	-5.89
Interest Expense	-2.57	-2.51	-0.9	-2.1	-0.93	-0.01
Interest & Investment Income	-	-	-	-	-	0
Other Non Operating Income (Expenses)	0.02	0.27	0.15	0	-0.4	-
EBT Excluding Unusual Items	-10.02	-9.73	-14.92	-12.37	-8.88	-5.9
Gain (Loss) on Sale of Assets	-3.14	-	-	-	-	-
Asset Writedown	-0.1	-	-	-	-	-
Other Unusual Items	-	-	-	0.2	-	-
Pretax Income	-13.26	-9.73	-14.92	-12.17	-8.88	-5.9
Income Tax Expense	-	0.01	0	0	0	0
Net Income	-13.26	-9.74	-14.92	-12.17	-8.88	-5.9
Net Income to Common	-13.26	-9.74	-14.92	-12.17	-8.88	-5.9
Shares Outstanding (Basic)	46	13	4	1	0	0
Shares Outstanding (Diluted)	46	13	4	1	0	0
Shares Change (YoY)	608.91%	252.66%	165.79%	470.01%	71.71%	45.69%
EPS (Basic)	-0.29	-0.77	-4.18	-9.06	-37.68	-43.00
EPS (Diluted)	-0.29	-0.77	-4.18	-9.06	-37.68	-43.00
Free Cash Flow	0.25	-1.32	-3.95	-8.01	-2	-3.52
Free Cash Flow Per Share	0.01	-0.10	-1.11	-5.96	-8.48	-25.64
Gross Margin	-33.22%	16.64%	39.11%	64.99%	83.74%	74.04%
Operating Margin	-722.63%	-347.28%	-211.92%	-222.99%	-440.83%	-255.58%
Profit Margin	-1282.82%	-451.70%	-223.23%	-264.33%	-519.33%	-255.94%
Free Cash Flow Margin	23.85%	-61.21%	-59.04%	-173.90%	-116.82%	-152.63%
EBITDA	-6.78	-6.09	-12.73	-9.72	-6.75	-5.66
EBITDA Margin	-	-282.34%	-190.46%	-211.21%	-	-245.52%
D&A For EBITDA	0.69	1.4	1.43	0.54	0.78	0.23
EBIT	-7.47	-7.49	-14.17	-10.27	-7.54	-5.89
EBIT Margin	-	-	-211.92%	-222.99%	-	-255.58%
Revenue as Reported	1.03	2.16	6.69	4.6	1.71	2.31
Advertising Expenses	-	-	-	-	-	0.33

Source: S&P Global Market Intelligence. Standard template. Financial Sources.